By Connor Hart
Edesa Biotech named Peter Weiler as its finance chief, succeeding Stephen Lemieux, effective May 1.
Weiler, 56, has experience in finance and corporate strategy with both the biotechnology and pharmaceutical industries, the Toronto-based company said Friday.
He most recently was president of Exzell Pharma, a privately held, commercial-stage pharmaceutical company. Prior, he held executive posts at companies including Biosyent and Cipher Pharmaceuticals, as well as research and financial positions at Eli Lilly Canada.
Weiler will receive an annual base salary of $300,000. He will additionally be eligible for a target annual bonus valued at 40% of his base salary, as well as other benefits, according to a filing with the Securities and Exchange Commission.
Weiler succeeds Lemieux, who is stepping down as CFO to pursue other professional opportunities. He will continue to provide financial advisory services to Edesa on a contract basis following the planned transition, the company said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 04, 2025 16:41 ET (20:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.